Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TLSIW
Upturn stock ratingUpturn stock rating

TriSalus Life Sciences Inc. (TLSIW)

Upturn stock ratingUpturn stock rating
$1.29
Last Close (24-hour delay)
Profit since last BUY-33.85%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: TLSIW (1-star) is a SELL. SELL since 1 days. Profits (-33.85%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$1.29
high$

Analysis of Past Performance

Type Stock
Historic Profit -61.61%
Avg. Invested days 31
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.47
52 Weeks Range 0.42 - 2.25
Updated Date 06/10/2025
52 Weeks Range 0.42 - 2.25
Updated Date 06/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -84.67%
Operating Margin (TTM) -79.95%

Management Effectiveness

Return on Assets (TTM) -85.52%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 29370602
Shares Outstanding -
Shares Floating 29370602
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

TriSalus Life Sciences Inc.

stock logo

Company Overview

overview logo History and Background

TriSalus Life Sciences Inc. focuses on developing and commercializing innovative delivery systems for oncology. While specific founding dates and early milestones are limited in readily available public information, they've been progressing in targeted cancer therapeutics.

business area logo Core Business Areas

  • Drug Delivery Systems: Development and commercialization of drug delivery systems targeting liver and pancreatic tumors.
  • Immunotherapy: Enhancing the delivery and efficacy of immunotherapies directly to tumors.

leadership logo Leadership and Structure

Information on the complete leadership team structure and members is limited in readily available public resources. Public data details the CEO and CFO roles. Further details would require deeper analysis of company filings.

Top Products and Market Share

overview logo Key Offerings

  • TriNav Infusion System: A pressure-enabled drug delivery system designed to enhance therapeutic penetration into solid tumors, particularly in the liver. Market share data is currently not readily available in standardized reports. Competitors include companies that offer regional cancer therapies or infusion devices.
  • Match Trial Program: Trial of combination of TriNav with checkpoint inhibitor. Market share data is currently not readily available in standardized reports. Competitors include companies that offer regional cancer therapies or checkpoint inhibitor therapies.

Market Dynamics

industry overview logo Industry Overview

The oncology therapeutics market is rapidly growing, driven by increasing cancer incidence and advancements in targeted therapies and immunotherapies. Demand for improved drug delivery methods is increasing.

Positioning

TriSalus is positioned as an innovator in regional cancer therapies, focusing on improving drug delivery to solid tumors. They have a competitive advantage based on their pressure-enabled drug delivery technology.

Total Addressable Market (TAM)

The total addressable market for liver and pancreatic cancer therapeutics is multi-billion dollar. TriSalus is positioned to capture a significant share of this market with their targeted drug delivery systems. Specific TAM estimates depend on market segmentation and growth projections.

Upturn SWOT Analysis

Strengths

  • Proprietary pressure-enabled drug delivery technology
  • Focus on difficult-to-treat solid tumors
  • Potential for improved therapeutic efficacy and reduced systemic toxicity
  • Pipeline of drug delivery systems and combination therapies

Weaknesses

  • Limited market presence and commercial infrastructure
  • Reliance on clinical trial outcomes for product approval and adoption
  • Competition from established pharmaceutical and medical device companies
  • Relatively small company size

Opportunities

  • Expanding clinical applications of drug delivery systems
  • Partnering with pharmaceutical companies to develop combination therapies
  • Securing regulatory approvals and reimbursement for products
  • Acquiring or licensing complementary technologies

Threats

  • Regulatory hurdles and delays
  • Clinical trial failures
  • Competition from alternative therapies
  • Pricing pressures from healthcare payers

Competitors and Market Share

competitor logo Key Competitors

  • CRIS
  • Varian Medical Systems (Siemens Healthineers)
  • Boston Scientific (BSX)

Competitive Landscape

TriSalus has a competitive advantage in targeted drug delivery. However, larger companies have more market power and product ranges. They must continue to innovate and produce positive clinical results.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data requires access to specific quarterly and annual reports. Public information is limited.

Future Projections: Future projections depend on clinical trial outcomes, regulatory approvals, and market adoption of their products. Analyst estimates are not readily available and are rapidly changing.

Recent Initiatives: Recent initiatives focus on advancing clinical trials of their drug delivery systems and exploring potential partnerships.

Summary

TriSalus Life Sciences Inc. is a small company pioneering targeted drug delivery in oncology. It has innovative technology but needs to demonstrate clinical efficacy and commercial success. Challenges include competition from larger players, regulatory hurdles, and the need for partnerships. The company's future depends on securing regulatory approvals and expanding the use of its drug delivery systems. They have a long way to go.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Press Releases
  • Market Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data is based on limited public information and may not be comprehensive.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About TriSalus Life Sciences Inc.

Exchange NASDAQ
Headquaters Westminster, CO, United States
IPO Launch date 2023-08-11
CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A.
Sector Healthcare
Industry Medical Devices
Full time employees 110
Full time employees 110

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.